ESR1 and breast carcinoma: In 2023, Xie et al. disclosed a series of degradants based on the oxabicycloheptane sulfonamide (OBHSA) scaffold, among which compound ZD12 exhibited excellent anti-tumor efficacy and ERα degradation activity superior to Fluvastatin in both Tamoxifen-sensitive and -resistant breast cancer mouse models (Burslem and Crews, 2020).